Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects

Clinical Therapeutics

Volumn 33, Issue 9, 2011, Pages 1142-1149

  Martinsson Niskanen, Titti ^a   Riisbro, Rikke ^b   Larsson, Leonard ^a   Winstedt, Lena ^a   Stenberg, Yvonne ^a   Pakola, Steve ^c   Stassen, Jean Marie ^c   Glazer, Steven ^a  

^a BioInvent International AB   (Sweden)

^b Cyncron A/S   (Denmark)

^c ThromboGenics NV   (Belgium)

Author keywords

Angiogenesis; Anti placental growth factor; Cancer; Monoclonal antibody; Phase I study

Indexed keywords

BLOOD CLOTTING FACTOR; DRUG ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TB 403; PLACEBO; PLACENTAL GROWTH FACTOR; RO 5323441; UNCLASSIFIED DRUG; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BACKACHE; BLOOD SAMPLING; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EAR DISEASE; ELECTROCARDIOGRAM; EPIDIDYMITIS; HERPES SIMPLEX; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFECTION; INFESTATION; INJECTION SITE BLEEDING; INNER EAR DISEASE; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; NECK PAIN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH PAIN; URINALYSIS; VITAL SIGN; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PREGNANCY PROTEINS; PROTEIN BINDING; VASCULAR ENDOTHELIAL GROWTH FACTOR A; YOUNG ADULT;

EID: 80053041612     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2011.08.007     Document Type: Article

References (21)

1. Rizzo C., Yin X., Ljungars A., Packman K., et al. RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced phosphorylation in vitro and tumor growth in vivo [abstract]. Cancer Res 2011, 70. Washington, DC, AACR, Philadelphia (PA), Abstract 1370.
2. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
3. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134. TARGET Study Group.
4. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
5. Carmeliet P., Moons L., Luttun A., et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001, 7:575-583.
6. Fischer C., Jonckx B., Mazzone B., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
7. Fischer C., Mazzone M., Jonckx B., Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?. Nat Rev Cancer 2008, 8:942-956.
8. Ho M.C., Chen C.N., Lee H., et al. Placenta growth factor not vascular endothelial growth factor A or C can predict the early recurrence after radical resection of hepatocellular carcinoma. Cancer Lett 2007, 250:237-249.
9. Taylor A.P., Osorio L., Craig R., et al. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy. Clin Cancer Res 2002, 8:1213-1222.
10. Taylor A.P., Rodriguez M., Adams K., et al. Altered tumor vessel maturation and proliferation in placenta growth factor-producing tumors: potential relationship to post-therapy tumor angiogenesis and recurrence. Int J Cancer 2003, 105:158-164.
11. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
12. ICH Topic E6, Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) European Medicines Agency, Accessed August 25, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf.
13. Bottomley M.J., Webb N.J., Watson C.J., et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol 2000, 119:182-188.
14. Matsumoto K., Suzuki K., Koike H., et al. Prognostic significance of plasma placental growth factor levels in renal cell cancer: an association with clinical characteristics and vascular endothelial growth factor levels. Anticancer Res 2003, 23:4953-5958.
15. ICH Topic Q2, Note for Guidance on Validation of Analytical Procedures (CPMP/ICH/381/95) European Medicines Agency, Accessed August 25, 2011. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002662.pdf.
16. Guidance for Industry, Bioanalytical Method Validation US Food and Drug Administration, Accessed August 25, 2011. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf.
17. Rowland M., Tozer T.N. Clinical Pharmacokinetics, Concepts and Applications 1995, Williams & Wilkins, Baltimore, Md. 3rd ed.
18. Mire-Sluis A.R., Barrett Y.C., Devanarayan V., et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004, 289:1-16.
19. Mould D.R., Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies. Biodrugs 2010, 24:23-39.
20. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
21. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.